Prof. Shani Paluch-Shimon

Medical Oncologist
Breast Oncology Lab, Director

The Breast Oncology Lab at the Hadassah Cancer Research Institute, led by Dr. Paluch-Shimon, is devoted to advancing clinical studies for the detection and prevention of breast cancer in young women. Current projects are focused on BRCA-associated breast cancer and triple negative breast cancer and neo-adjuvant therapies. The goal of this research is to provide a more personalized and precise treatment for breast cancer patients, and Shani and her team believe this can be accomplished by acknowledging that breast cancer is not one illness, and that treatment must be specifically tailored to the biology of an individual patient.

In addition to her responsibilities at HCRI, Shani is the subject editor for breast cancer treatment guidelines for the European Society of Medical Oncology, key-faculty in several international oncology societies & multi-stake holder organizations and member of the Israeli National Cancer Council. She completed the Talpiot physician leadership program at Sheba Medical Center and holds a masters degree in epidemiology from the London School of Hygiene & Tropical Medicine.

Recent Key Publications
  • Pembrolizumab for Early Triple-Negative Breast Cancer. The New England Journal of Medicine, 2020. Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O’Shaughnessy J,
  • Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. The New England Journal of Medicine, 2022. Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O’Shaughnessy J.
  • MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology, 2017. Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A.
  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. New England Journal of Medicine, 2017.Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O’Shaughnessy J.
  • Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations. Journal of Clinical Oncology, 2020. Lambertini M, Ameye L, Hamy AS, Zingarello A, Poorvu PD, Carrasco E, Grinshpun A, Han S, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Cortesi L, Senechal C, Miolo G, Pogoda K, Pérez-Fidalgo JA, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz MDP, Villarreal-Garza C, Dieci MV, Clatot F, Berlière M, Graffeo R, Teixeira L, Córdoba O, Sonnenblick A, Luna Pais H, Ignatiadis M, Paesmans M, Partridge AH, Caron O, Saule C, Del Mastro L, Peccatori FA, Azim HA Jr.
  • Genetic testing in patients with triple-negative or hereditary breast cancer. Current Opinion in Oncology, 2021. Bernstein-Molho R, Evron E, Yerushalmi R, Paluch-Shimon S.
  • ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.  ESMO Open, 2020. de Azambuja E, Trapani D, Loibl S, Delaloge S, Senkus E, Criscitiello C, Poortman P, Gnant M, Di Cosimo S, Cortes J, Cardoso F, Paluch-Shimon S, Curigliano G.
Linkedin-in
HCRI
Immuno Oncology
Contact Us
Copyright Hadassah Medical Organization and HCRI © 2024 All rights reserved
Skip to content